Longitudinal monitoring of HR expression and AP-1 biomarkers via liquid biopsies enables adaptive therapy switching, transforming resistance mechanisms into actionable targets to prolong disease control in advanced breast cancer. This evidence concerns the gene FOS and breast cancer.